** Shares of drug developer Apogee Therapeutics APGE.O rise 35.9% to $64.50 premarket
** Company says its experimental drug met main goal in a mid-stage study to treat patients with moderate-to-severe atopic dermatitis (AD)
** AD, or eczema, is a chronic disease that causes inflammation, redness and irritation of skin
** Company says the drug, APG777, showed high response rate with a 71% reduction in eczema severity, compared with placebo of 33.8% at week 16 in part-A of the mid-stage study
** Company expects to share the 280-patient study data from part-B in mid-2026
** As of last close, stock up 4.77% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.